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1. Introduction  
Over the last decade, considerable effort has gone into defining global gene expression 
profiles (GEP) in many different types of malignancies. There is a dual aim behind these 
studies: on the one hand, to identify molecular signatures that correlate with clinically 
useful parameters and, on the other hand, to increase knowledge concerning the biology of 
the respective diseases. Some of these studies yielded molecular classifications of specific 
cancer types that better correlate with disease progression and/or response to therapy, 
whereas others revealed yet unknown biological properties of cancer cells that may 
represent the starting point for novel therapeutic approaches. 
Acute myeloid leukemias (AML) represent a highly heterogeneous set of malignancies 
whose pathogenesis is linked to specific genetic abnormalities, including chromosome 
translocations and point mutations that involve genes encoding for key regulators of 
hematopoiesis (Marcucci, Haferlach, & Dohner 2011). Genetic information is the most 
relevant parameter for the correct classification of AML patients at diagnosis into three 
prognostic risk groups (favorable, intermediate and adverse) and, consequently, for 
directing therapeutic choices (Lo-Coco et al. 2008; Dohner et al. 2010). In fact, current 
diagnostic approaches include cytogenetic and molecular analyses for correct stratification 
of AML patients according to the World Health Organization (WHO) recommendations 
(Vardiman et al. 2009). However, these approaches are not fully satisfactory, particularly 
within the significant group of cytogenetically normal AML (CN-AML), where known 
prognostic markers are lacking. This likely reflects the genetic heterogeneity of the CN-AML 
group, the existence of yet unidentified genetic lesions and the co-existence of different 
genetic mutations in a significant number of cases.  
AML was the first type of malignancy to be studied with a GEP approach, and hundreds of 
reports addressing specific clinical issues (classification, prognosis, response to therapy) 
have been published. An equally significant number of studies have addressed the 
molecular pathogenesis of AML by analyzing GEP in functionally characterized AML model 
systems, including transgenic mice, primary or established cell lines expressing 
leukemogenic oncogenes. The analysis of their specific target genes has been exploited to 
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unravel the functional consequences of AML-associated oncogene expression, including the 
arrest of myeloid differentiation and enhanced cell survival.  
In recent years, the analysis of AML has been extended to other genomic approaches, 
including microRNA profiling and epigenetic studies. The rapid technological 
advancement, and in particular the advent of next-generation sequencing has imposed a 
dramatic change of outlook to the molecular basis of cancer, including AML, and it is likely 
that GEP approaches so far used will become obsolete, favoring more focused, clinically 
relevant expression studies.  
What have GEP studies taught us about AML? We here propose an overview of the 
progress that has been made through GEP both in terms of clinical utility and of insight to 
the biology of the disease, and discuss future perspectives (Figure 1). 
  
 
Fig. 1. Main points covered in this review. 
2. Clinical utility of GEP analysis in AML  
The first evidence that GEP could be employed as a tool for the correct classification of 
cancer was reported by Golub and collaborators in 1999, using acute leukemias as a test case 
(Golub et al. 1999). The authors were able to discriminate AML samples from acute 
lymphoblastic leukemia (ALL) samples without prior knowledge concerning the respective 
diagnosis, and suggested two important applications for GEP: “class discovery”, which 
refers to the identification of new prognostically relevant tumor subtypes, and “class 
prediction”, which assigns tumor samples to already known subtypes on the basis of their 
specific gene expression signature. Successive studies introduced the possibility to exploit 
GEP for predicting response to therapy (“outcome prediction”) (Theilgaard-Monch et al. 
2011). Technically, class discovery implies the search for significant similarities and 
differences in a cohort of samples, assuming that similar gene expression signatures will 
correspond to the same disease subtype, and relies on an unsupervised approach (i.e. no 
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prior knowledge of patient characteristics, such as age, cytogenetics, molecular 
abnormalities, etc.). Class prediction, instead, takes into account patient information to 
derive gene expression signatures that are specific for given parameters, which can then be 
used for predicting disease subtypes in samples of unknown status (i.e. supervised 
approach).  
In de novo AML, chromosomal abnormalities can be detected at diagnosis in approximately 
55% of cases by cytogenetics analysis, and specific genetic mutations can be identified in 
85% of the remaining CN-AML. The most frequent chromosomal rearrangements include 
reciprocal translocations and inversions, such as t(8;21), which fuses the AML1 and ETO 
genes, inv(16), which results in the CBF┚/MYH11 chimeric gene, t(15;17), which generates 
the PML/RAR┙ fusion specific of acute promyelocytic leukemia (APL), and a variety of 
translocations involving the MLL gene on chromosome 11q23, the most frequent being 
t(9;11) (Look 1997). The resulting fusion proteins possess oncogenic properties and 
frequently function as transcriptional regulators (Alcalay et al. 2001). It is therefore perhaps 
not surprising that AML blasts bearing such rearrangements display specific gene 
expression signatures, as demonstrated by several studies (Bullinger et al. 2004; Debernardi 
et al. 2003; Schoch et al. 2002; Valk et al. 2004). In fact, GEP can actually predict favorable 
cytogenetic AML subtypes, i.e. t(8;21), t(15;17) and inv(16), with 100% accuracy, and with 
>90% accuracy for AML with MLL rearrangements (Haferlach et al. 2005b; Ross et al. 2004), 
whereas the correlation is less stringent for other molecular subtypes (Verhaak et al. 2009).  
The function of group-specific genes often reflects characteristics of the corresponding 
disease: for example, the t(15;17) signature of APL, which is clinically characterized by a 
hemorrhagic diathesis and a response to treatment with Retinoic Acid (RA), includes genes 
involved in hemostasis and suggests an impairment in the response to RA-induced 
differentiation (Bullinger et al. 2004). Interestingly, GEP can segregate APL cases (M3 
subtype) from variant cases (M3v), which are characterized by a specific morphology of 
blasts and by a more severe prognosis (Haferlach et al. 2005a). The genes that are 
differentially expressed between APL-M3 and APL-M3v encode for functions such as 
granulation and maturation of blood cells, which are coherent with the morphological and 
clinical observations. 
Specific somatic mutations are frequent events in AML, particularly in CN-AML, which are 
classified in the group with intermediate risk even though there are important differences. 
Currently, only mutations of the NPM1, CEBPA and FLT3 genes have an impact on the 
clinics because of their correlation with prognosis. Other recurrent mutations in AML 
include N-RAS, KIT, IDH1, IDH2, WT1, RUNX1 and MLL, but their clinical significance is 
either controversial or unknown, and their identification is at the moment not used for 
guiding therapeutic choices. Although these mutations are prevalent in CN-AML, they can 
also be found in association to other cytogenetic abnormalities (Marcucci, Haferlach, & 
Dohner 2011).  
Specific GEP signatures have been described for AML that carry mutations, but their 
predictive accuracy appears to be lower than the one described for the recurrent cytogenetic 
rearrangements described above (Verhaak et al. 2009), likely due to the frequent co-
occurrence of different genetic abnormalities or to the presence of other yet unknown 
mutations. Mutations in the NPM1 gene represent the most frequent genetic abnormality in 
CN-AML (Falini et al. 2005), and are associated to mutations of the FLT3 gene in a 
significant proportion of cases. AML with mutated NPM1 without concurrent FLT3 
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
200 
mutations are characterized by a better response to induction therapy and a favorable 
prognosis (Falini et al. 2007). These cases present a gene expression signature characterized 
by over-expression of HOX and TALE genes (Alcalay et al. 2005; Verhaak et al. 2005). Other 
genes involved in maintenance of hematopoietic stem cells, such as the NOTCH ligand 
JAG1, are also over-expressed, suggesting that the cell of origin of AML with mutated NPM1 
may be an early hematopoietic progenitor, as further indicated by frequent multilineage 
involvement (Alcalay et al. 2005; Pasqualucci et al. 2006). 
AML with CEBPA mutations are also associated with a favorable outcome. Generally, AML 
in this group carry mutations in both CEBPA alleles, whereas heterozygous mutations are 
less frequent. A specific GEP signature has been described for AML with biallelic CEBPA 
mutations, while no discriminating gene expression pattern was detectable in AML carrying 
single mutations (Wouters et al. 2009). Of note, in this study, only AML with biallelic 
CEBPA mutations correlated with a favorable outcome, whereas single mutations did not, 
suggesting a prognostic value for the specific gene expression signature. Interestingly, in a 
group of CN-AML patients displaying a GEP signature resembling that of AML with 
mutant CEBPA, but lacking such mutations, the CEBPA gene was found to be silenced as a 
consequence of promoter hypermethylation (Wouters et al. 2007). This result suggests that 
GEP may actually be more efficient than mutational analysis in identifying functional 
pathways that are perturbed in specific AML cases, and may be a useful tool for correct 
molecular classification of AML . 
Two types of mutations involving FLT3 can be found in AML: internal tandem duplications 
(FLT3-ITD), which are present in 20% of AML, and point mutations within the tyrosine 
kinase domain (FLT3-TKD) that can be detected in an additional 5-10% of cases. FLT3-ITD 
are associated with a poor prognosis in CN-AML, whereas the prognostic relevance of FLT3-
TKD is not clear (Marcucci, Haferlach, & Dohner 2011; Mrozek et al. 2007). GEP analyses in 
AML with mutated FLT3 have yielded controversial results. One study described an 
accurate separation of samples with FLT3-ITD from those with FLT3-TKD (Neben et al. 
2005), while another study reported a specific gene expression signature that discriminates 
between FLT3-TKD and FLT3-wild type CN-AML (Whitman et al. 2008). On the other hand, 
other studies reported difficulties in predicting FLT3 mutations from GEP results (Valk et al. 
2004; Verhaak et al. 2009). Such conflicting results may reflect the frequent coincidence of 
FLT3 mutations with other mutations in CN-AML (Dohner et al. 2010), where the co-
occurrence of several genetic abnormalities is likely to impact on the phenotype and the 
specific GEP. Interestingly, however, a specific gene expression signature derived from 
FLT3-ITD CN-AML, although not highly accurate in predicting the FLT3-ITD genotype, 
proved to be extremely accurate in predicting clinical outcome (Bullinger et al. 2008), 
suggesting that activation of the FLT3 pathway may be mediated by other yet unidentified 
genetic alterations. 
In summary, GEP has proven to be extremely reliable in identifying AML cases with 
recurrent chromosomal abnormalities, but less predictive in identifying specific gene 
mutations in CN-AML (Verhaak et al. 2009), and this raises doubts as to its applicability in a 
clinical setting. However, a recent multicenter study involving 11 laboratories that use 
different microarray platforms (MILE – Miocrarray Innovations in Leukemia) demonstrated 
that GEP is a robust technology for the diagnosis of hematologic malignancies with high 
accuracy (Haferlach et al. 2010), and that in some cases GEP outperformed routine 
diagnostic procedures. The analysis of larger cohorts of AML cases, in particular of the less 
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frequent molecular subtypes, will likely be necessary for the identification of reliable gene 
expression signatures of clinical utility. Whether GEP-derived predictors can be of use for 
prognosis, and in particular whether GEP presents a concrete advantage over standard 
cytogenetic or molecular markers in terms of prognostic value, remains an open question. 
Different studies have identified specific gene expression signatures that correlate with 
clinical outcome in AML (Bullinger et al. 2004; Metzeler et al. 2008; Radmacher et al. 2006), 
suggesting that GEP may, in fact, yield diagnostic and prognostic information 
simultaneously.  
3. GEP and the biology of AML 
As discussed above, GEP results derived from AML patients have been exploited to 
derive information concerning the biology underlying the disease. For the purpose of 
identifying specific functional pathways relevant to leukemogenesis, this approach is, 
however, partially hampered by properties that are intrinsic to patient-derived material, 
including individual genetic variability and the presence of heterogeneous cellular 
populations in each sample. It is, therefore, possible to exploit different experimental 
model systems, including purified cellular subpopulations, cell lines or animal models, 
with the aim of unraveling the molecular mechanisms underlying leukemic 
transformation. Such approaches have been widely proved to be reliable by extensive 
validation through a variety of independent methods. A significant number of reports 
have identified transcriptional targets deregulated in specific types of AML, and it is not 
possible to discuss all the data and their implications in due detail. We will instead briefly 
review specific aspects that emerged from these studies, focusing on their possible 
relevance to AML pathogenesis and management. 
3.1 Common functions: Myeloid differentiation and stem cell maintenance 
A general feature of AML-associated oncogenes is the capacity to block the process of 
myeloid differentiation and to promote self-renewal of hematopoietic precursor/stem cells. 
A variety of model systems have been employed for GEP analyses with the aim of 
identifying specific genes and pathways underlying these properties. Some of these studies 
have highlighted the existence of target genes that are common to several AML-associated 
oncogenes, suggesting that diverse genetic mutations can lead to the deregulation of 
overlapping downstream functional pathways. This observation is of potential clinical 
importance, since it suggests the existence of common therapeutic targets, regardless of the 
specific initiating oncogenic lesion. For example, expression of AML fusion proteins such as 
AML1/ETO, PML/RAR, and PLZF/RAR in the U937 hematopoietic cell line resulted in 
deregulation of a large set of common targets (Alcalay et al. 2003). These included a 
decreased expression of genes involved in myeloid differentiation, such as GFI1, CSF3R, 
STAT5A and others, and the activation of pathways leading to increased stem cell renewal 
(in particular, the Jagged1/Notch pathway). A similar approach led to the identification of 
Wnt signaling activation by diverse AML oncogenes, through upregulation of plakoglobin 
expression (Muller-Tidow et al. 2004). The existence of common leukemogenic functions is 
further suggested by the observation that a specific cellular subpopulation derived from 
CEBPA-deficient leukemia, which is capable of transferring AML to recipient mice, revealed 
a GEP signature shared with MLL-AF9-transformed AML (Kirstetter et al. 2008). 
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The identification of overlapping functions deregulated by AML oncogenes is perhaps to be 
expected. In fact, the genetic lesions underlying AML pathogenesis mostly involve 
transcriptional regulators that function during myeloid differentiation in an orchestrated 
manner, and are physiologically cross-regulating each other’s expression. For example, 
CEBPA is a crucial factor in myeloid differentiation, and its expression is often attenuated or 
repressed by oncogenic transcription factors such as AML1/ETO (Pabst et al. 2001). 
Therefore, part of the transcriptional response elicited by AML1/ETO may be due to a 
decrease in CEBPA activity. Overexpression of CEBPA in human CD34+ hematopoietic 
precursors induces the expression of genes involved in myeloid differentiation (Cammenga 
et al. 2003), which are presumably targets of deregulation not only in AML with mutated 
CEBPA, but also in all AML that present decreased levels of CEBPA expression. 
Interestingly, mutations involving genes that do not directly regulate gene expression, such 
as FLT3 or NPM1, are associated to alterations in global gene expression that partially 
overlap with those described for oncogenic transcription factors. Expression of FLT3 
mutants in murine 32Dcl3 cells resulted in repression of genes involved in myeloid 
differentiation, including CEBPA, and in the activation of a transcriptional program that 
partially overlaps with that induced by IL-3, a potent hematopoietic cytokine (Mizuki et al. 
2003). Recently, the expression of an NPM1 mutant allele in mouse HSC was shown to result 
in HOX gene overexpression, reproducing the situation of primary AML with mutated 
NPM1 (Vassiliou et al. 2011). The molecular mechanisms through which these mutants elicit 
a transcriptional response remain to be elucidated. 
3.2 Characterization of Leukemic Stem Cells 
AML derives from the transformation of a single hematopoietic progenitor/stem cell, 
known as leukemic stem cell (LSC), which shares important properties with normal 
hematopoietic stem cells (HSC), including unlimited self-renewal and the capacity to give 
origin to a hierarchy of hematopoietic cells. The molecular characterization of LSC and the 
identification of functions that are specific of LSC with respect to normal HSC are clearly 
instrumental for designing novel therapeutic strategies aimed at eradicating AML. 
The transforming genetic event does not necessarily occur in HSC, but may take place in 
more differentiated progenitors that reacquire stem cell characteristics (Passegue et al. 2003). 
In favor of the latter possibility, Krivtsov et al. isolated leukemic stem cells (LSC) from a 
mouse model of AML generated by the MLL-AF9 fusion protein, which revealed a GEP that 
was reminiscent of normal granulocyte/macrophage progenitors (Krivtsov et al. 2006). 
However, a subset of genes that is highly expressed in normal HSC appeared to be re-
activated in LSC, including several HOXA genes, STAT1 and CD44. Another study 
conducted on CD34+ AML revealed two distinct subpopulations of LSC, the more mature 
resembling normal granulocyte-macrophage progenitors in terms of GEP, and the immature 
LSC population reminiscent of lymphoid-primed multipotent progenitors (Goardon et al.). 
Taken together, these studies and the ones discussed in the previous section suggest that 
AML initiates in progenitor cells that re-acquire specific stem cell characteristics, such as 
activation of Notch and/or Wnt signaling and/or over-expression of HOX genes, which are 
tightly linked to the acquisition of an unlimited self-renewal capacity and cause an arrest in 
the differentiation program.  
However, the identification of functions that are specific of LSC with respect to normal HSC 
is clearly of importance for the identification of novel therapeutic strategies aimed at 
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eradicating AML. In terms of global gene expression, LSCs are not simply characterized by 
the re-activation of stem cell pathways and maintenance of self-renewal. A direct 
comparison of the GEP of highly enriched normal human HSC and LSC from AML of 
diverse subtypes revealed differences in relevant functional pathways, including Wnt 
signaling, MAP Kinase signaling, and Adherens Junction (Majeti et al. 2009). The latter is 
particularly intriguing, since it suggests specific abnormalities in the relationship between 
LSCs and the microenvironment (“niche”).  
3.3 Response to therapy 
AML are characterized by a heterogeneous response to therapy, and although there has 
been notable progress in the past decades, most patients still succumb to the disease. The 
search for new therapeutic strategies is therefore of paramount importance, and GEP studies 
have also been exploited to dissect the molecular basis underlying the response to AML 
therapy.  
One way to identify genes/pathways that may determine response to therapy is to compare 
GEP of treated versus untreated AML cells. Among AML, APL represents an exception in 
that its exquisite sensitivity to RA and arsenic trioxide treatment has dramatically changed 
its prognosis to a 5-year survival rate of 90%. Several studies have described specific 
transcriptional programs that are modulated by RA in APL cells, with the aim of identifying 
targets that may be of wider use in AML treatment. GEP analysis of APL blasts and 
PML/RAR-expressing U937 cells treated with RA in vitro revealed that the transcriptional 
response to RA is characterized by regulation of genes involved in the control of 
differentiation, stem cell self-renewal and chromatin remodeling, suggesting that specific 
structural changes in local chromatin domains may be required to promote RA-mediated 
differentiation (Meani et al. 2005).  
Another possible approach is to compare the GEP of sensitive versus resistant AML cells 
after treatment with drugs. Tagliafico et al. derived a molecular signature that predicts the 
resistance or sensitivity to differentiation induced by RA or vitamin D in six myeloid cell 
lines, and proved its validity in a set of primary AML blasts using an in vitro differentiation 
assay (Tagliafico et al. 2006). Similarly, Zuber at al., described the differences between a 
chemosensitive and a chemoresistant AML model: murine AML expressing the AML1/ETO 
fusion protein, which show a dramatic response to chemotherapy, displayed activation of 
the p53 tumor suppressor function. Murine AML expressing MLL fusion proteins are 
instead drug-resistant and present an attenuated p53 response. It appears, therefore, that the 
p53 network has a central role in the response to chemotherapy in AML (Zuber et al. 2009). 
Importantly, GEP information can also be exploited for the identification of new therapeutic 
options. Corsello et al. defined an AML1/ETO GEP signature by comparing a t(8;21) bearing 
cell line before and after siRNA-mediated inhibition of the fusion protein, and used the 
resulting signature to screen a set of drug-induced expression profiles (Corsello et al. 2009). 
In a recent study, publicly available GEP data sets derived from APL patients were 
exploited for the identification of an “APL signature”, which was then compared to a 
collection of expression profiles for more than 1300 bioactive compounds for the discovery 
of relevant drug candidates (Marstrand et al. 2010). Although these studies have not yet 
been transferred to the clinics, they open a concrete possibility for exploiting GEP data 
alongside chemical genomics approaches for the in silico identification of molecularly 
targeted drugs. 
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4. Conclusion and perspectives 
Have GEP studies truly had an impact on the management of AML? Currently, no GEP-
based diagnostic/prognostic tests are available for AML in clinical practice. However, tests 
that reliably predict the outcome for cancer patients based on the expression pattern of a 
selected subset of genes identified through GEP are available for other malignancies, such as 
breast cancer (van't Veer&Bernards 2008), and available evidence suggests that a reliable set 
of prognostic predictors could be established for AML as well. Furthermore, GEP can 
accurately sub-classify most AML according to the underlying genetic abnormality even 
when histopatholgical data are ambiguous, and outperforms routine diagnostic tests in 
certain cases, raising the possibility to introduce GEP-derived approaches in a diagnostic 
setting. A particularly exciting perspective is to exploit GEP data in combination with 
chemical genomics for the design of novel therapeutic strategies aimed at molecular targets. 
Many factors concur in determining the AML phenotype, and in recent years there has been 
a growing interest in high-throughput approaches other than GEP to analyze microRNA 
(miRNA) expression, epigenetic modifications and whole-genome DNA sequencing in 
AML. MiRNAs are small non coding RNAs that can regulate the expression levels of 
numerous target mRNAs both at the transcriptional and post-transcriptional level. Similarly 
to what has been observed for mRNAs, specific miRNA signatures have been associated 
with AML subtypes (Garzon et al. 2008; Li et al. 2008; Marcucci et al. 2008), and may 
therefore represent an additional option for the development of clinically useful tools. 
Epigenetic modifications including DNA methylation and covalent histone modifications, 
such as acetylation, methylation and ubiquitination, are known to play a crucial role in the 
regulation of gene expression, and different epigenetic alterations have been described in 
leukemias (Plass et al. 2008). Recently, specific DNA methylation profiles have been 
described for distinct cytogenetic and molecular AML subtypes, and a 15-gene methylation 
classifier was found to be predictive of overall patient survival (Figueroa et al. 2010). 
Interestingly, the integration of DNA methylation data with GEP was shown to further 
improve prognostication in AML, suggesting that integration of genomic approaches may 
prove of clinical importance (Bullinger et al. 2010). 
The advent of next-generation sequencing technology has opened the possibility to 
investigate the complexity of cancer genomes, and the first complete sequence of a human 
malignancy reported was that of an AML genome (Ley et al. 2008). The authors identified 
ten somatic mutations, two of which had already been described (NPM1 and FLT3), while 
the other eight were novel. None of the latter were, however, detected in a cohort of 187 
AML cases, casting serious doubts as to their relevance in determining the leukemic 
phenotype. Successive studies using the same approach identified novel mutations in the 
IDH1 and DNMT3 genes that are instead recurrent in AML, underlining the power of this 
approach for the discovery of genetic alterations in cancer (Ley et al. 2010; Mardis et al. 
2009). However, these studies also highlighted the relevant genetic heterogeneity among 
AML patients within the same subtype, since most of the mutations described were actually 
specific to the single patient under analysis, and their contribution to AML progression 
remains to be defined. One distinct possibility is that they represent “passenger” mutations 
that arise as a consequence of cancer-associated genomic instability, and bear no functional 
relevance to the malignant phenotype. On the other hand, such mutations may instead 
involve different players within complex functions (for example, regulators of proliferation 
or differentiation), and although the mutated genes are different, the functional 
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consequence(s) may be the same. In any case, the co-existence of several genetic alterations 
within the same cell is bound to have an impact on gene expression, and  it will therefore be 
necessary to integrate GEP data with the corresponding results from mutational analyses. 
Finally, microarray technology has inherent limitations, and with the advancement of 
current sequencing approaches may rapidly become obsolete. The possibility to sequence 
entire transcriptomes (RNA-seq) has several advantages over microarray-based GEP, 
including transcription start site mapping, gene fusion detection, small RNA identification 
and detection of alternative splicing events (Ozsolak & Milos 2011). The first RNA-seq 
analysis of an AML model reported an unexpected level of transcriptome variation between 
phenotypically similar LSC, including a large number of structural differences such as 
alternative splicing and promoter usage (Wilhelm et al. 2011). These results suggest a broad 
transcriptional heterogeneity in AML that is not limited to differences in mRNA levels. 
In the next few years there will inevitably be an explosion of genomic data in AML, 
describing yet unknown molecular mechanisms underlying the disease. The large amount 
of already available GEP data will have to be integrated with the new findings to increase its 
value in generating knowledge that can ultimately be translated into clinically useful tools. 
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